摘要
目的观察螺内酯对急性心肌梗死(AMI)患者血清单核细胞趋化蛋白-1(MCP-1)和白介素-1β(IL-1β)水平的变化。方法AMI患者共48例,随机分为对照组(n=23)和治疗组(n=25)。治疗组在对照组治疗的基础上加用螺内酯口服。分别用ELISA法和放射免疫法测定两组第1周、第6周血清MCP-1和IL-1β水平的变化,用心脏超声学检测两组第1周、第6周左室形态学参数和舒缩功能。结果与正常组相比,AMI后各组血清MCP-1和IL-1β水平均显著增高(均P>0.01)。第6周与对照组相比,治疗组血清MCP-1水平降低21.7%(P<0.01),血清IL-1β水平降低28.1%(P<0.01),LVEDVI明显减少(P<0.05)、VE/VA明显增加(P<0.01)。结论螺内酯可减轻AMI炎症反应过程,阻抑心室重构。
[Objective] To observe effects of spirolactone on serum mononcyte chemoattractant protein-1 （MCP-1） and interleukin-1β （IL-1β） in patients with acute myocardial infarction （AMI）. [Methods] 48 patients with AMI were divided into control group （n =23） and spironlactone group （n =25）. Serum MCP-1 and IL-1β were mearsured by enzyme linked immunosorbent assay and radioimmunoassy respectively. Two-dimensional, M-mode and Doppler utrasound recordings were abtained to determine the left ventricular anatomy and function. [Results] In comparison with control group, the levels of serum MCP-1 and IL-1β decreased 21.7% and 28.1% （P 〈0.05, respectively）, LVEDI were increased signticandy （P 〈0.05）, VE/VA were decreased significantly （ P 〈0.01） in sprironolactone group at 6th week. [ Conclusion] Inflammatory reaction and left ventricular remodeling may be inhibited by spirolactone.
出处
《中国现代医学杂志》
CAS
CSCD
北大核心
2009年第8期1257-1259,共3页
China Journal of Modern Medicine
基金
河北省科技厅计划课题(No:052761200)
